Exelixis, INC 10-K annual reports

Exelixis, Inc. announced robust financial results for 2025, driven by strong CABOMETYX sales and significant progress in its diverse oncology pipeline, including a zanzalintinib NDA submission.

Exelixis reports its eighth consecutive year of profitability with 11% revenue growth, driven by increased sales of cabozantinib and progress in its zanzalintinib development program.

Exelixis updates its Change in Control and Severance Benefit Plan, detailing eligibility, benefits, and limitations, while also providing insights into executive compensation and risk management strategies.